The FDA Black Box Warning Does Reduce the Use of Erythropoietin Stimulating Agents and Increases Blood Transfusions in Insured, Low Income Cancer Patients
Nov 1, 2014, 00:00 AM
10.1016/j.jval.2014.08.2392
https://www.valueinhealthjournal.com/article/S1098-3015(14)04322-8/fulltext
Section Title :
Disease-Specific Studies
Section Order :
1848
First Page :
A655
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(14)04322-8&doi=10.1016/j.jval.2014.08.2392